Approved indications
By IV or IM injection when oral therapy is not feasible, hydrocortisone sodium succinate is approved to treat: primary or secondary adrenocortical insufficiency and congenital adrenal hyperplasia; severe or incapacitating allergic conditions (e.g., asthma exacerbations, drug hypersensitivity, serum sickness); many corticosteroid‑responsive dermatologic, rheumatic, and respiratory diseases; certain ophthalmic, renal, gastrointestinal, hematologic, and neurologic conditions; hypercalcemia of malignancy; trichinosis with neurologic or myocardial involvement; tuberculous meningitis with block; and as palliative therapy in leukemias and lymphomas.

Off‑label uses and evidence
Clinicians may use IV hydrocortisone off‑label for septic shock (as stress‑dose corticosteroid) and for perioperative stress‑dose coverage in chronic steroid users or adrenal insufficiency; evidence from randomized trials and guidelines supports benefit in selected septic shock patients (mainly faster shock reversal) and prevention of adrenal crisis, though mortality benefits are modest or condition‑specific.

Efficacy expectations and onset
IV hydrocortisone has rapid onset, with high blood levels within minutes and clinical improvement in allergic reactions, asthma, or shock often beginning within hours; for chronic inflammatory or autoimmune diseases, meaningful symptom improvement may take several days. In adrenal insufficiency, stress‑dose therapy usually stabilizes blood pressure, electrolytes, and symptoms within hours to a day when combined with appropriate fluids and other treatments.

Comparison with other corticosteroids
Hydrocortisone is a short‑acting glucocorticoid with more mineralocorticoid (salt‑retaining) activity than prednisone or methylprednisolone, making it preferred for adrenal insufficiency but sometimes less convenient for long‑term anti‑inflammatory use. For severe inflammatory conditions, longer‑acting agents (e.g., methylprednisolone, dexamethasone) may require less frequent dosing and have less sodium retention, but overall anti‑inflammatory efficacy is similar when glucocorticoid‑equivalent doses are used.

Typical dosing and administration
Hydrocortisone sodium succinate is given by a healthcare professional as an IV injection, IV infusion, or deep IM injection; IV is usually preferred in emergencies. In adults, an initial dose of 100–500 mg is common, repeated every 2, 4, or 6 hours based on the condition and response, with a typical total daily range of about 100 mg to 1–2 g in severe illness. Pediatric dosing is weight‑ or surface‑area‑based (for example, about 0.16–1 mg/kg or 6–30 mg/m² per dose IV or IM, 1–2 times daily), adjusted to disease severity and clinical response. Doses are expressed in terms of hydrocortisone base, and solutions are prepared and diluted according to the specific product instructions.

Special dosing considerations
Higher “stress‑dose” regimens (for example, 100 mg IV followed by 50–100 mg every 6–8 hours) are often used in adrenal crisis, septic shock, or major surgery for adrenal‑insufficient patients, then tapered as the patient stabilizes. Because hydrocortisone has significant mineralocorticoid activity and short duration, chronic adrenal‑replacement regimens are usually transitioned to scheduled oral hydrocortisone once the patient can take medications by mouth. Long‑term systemic use for inflammatory diseases generally requires the lowest effective dose with gradual tapering to reduce adrenal suppression and relapse risk.

Missed dose and overdose
Because this medicine is typically given in hospitals or clinics, missed doses are uncommon and are managed by the clinical team. In settings where an emergency IM injection is prescribed for adrenal crisis, if a scheduled stress dose is missed, patients or caregivers are usually instructed to give it as soon as remembered and seek urgent medical advice. Overdose or very high cumulative dosing can cause severe fluid retention, dangerously high blood pressure, high blood sugar, confusion or psychosis, severe infection, and electrolyte imbalances; suspected overdose requires immediate medical evaluation and supportive treatment while gradually reducing the steroid dose.

Common side effects
With short‑term IV or IM use, people may experience increased appetite, fluid retention and swelling, elevated blood pressure, mood changes (such as irritability or euphoria), trouble sleeping, high blood sugar, or stomach upset. The likelihood and severity increase with higher doses and longer courses; many effects resolve after the dose is reduced or stopped.

Serious or rare adverse effects
Serious reactions can include severe infection or sepsis (because immunity is suppressed), stomach or intestinal bleeding or perforation, blood clots, heart failure worsening, psychiatric reactions (severe depression, mania, psychosis), vision problems such as glaucoma or cataracts, bone thinning and fractures, tendon rupture, and adrenal suppression that can lead to adrenal crisis if the drug is stopped abruptly after prolonged use. Rarely, life‑threatening allergic or anaphylactoid reactions have occurred during or shortly after injection and require emergency care.

Warnings and special populations
Use with caution in people with diabetes, high blood pressure, heart failure, kidney or liver disease, peptic ulcer disease, osteoporosis, mood disorders, active or latent infections (including tuberculosis, fungal, or parasitic infections), and in those recently having surgery or trauma. In pregnancy, hydrocortisone is used when clearly needed; long‑term or high‑dose use may affect fetal growth, and newborns of treated mothers should be monitored for adrenal suppression. Because hydrocortisone enters breast milk, prolonged high‑dose therapy may require monitoring the infant for poor growth or adrenal suppression and consideration of dose adjustment or feeding alternatives in consultation with clinicians. There is no strict lower age limit on label; infants and children are treated with weight‑based dosing but are at higher risk of growth suppression and bone loss with prolonged therapy.

Relative safety compared with other steroids
At equivalent anti‑inflammatory doses and durations, hydrocortisone has a side‑effect profile similar to other systemic corticosteroids, though its stronger mineralocorticoid activity may cause more fluid retention and electrolyte changes than agents like methylprednisolone or dexamethasone. Short courses at the lowest effective dose carry substantially less long‑term risk than repeated or chronic high‑dose use.

Reporting side effects and safety updates
Suspected side effects can be reported to the U.S. Food and Drug Administration through the MedWatch program (online or by phone) or to the product manufacturer’s safety line. Up‑to‑date safety communications, boxed warnings, and label changes are available on the FDA’s and manufacturer’s drug information websites.

Drug and supplement interactions
Hydrocortisone may interact with many medicines. Enzyme‑inducing drugs such as rifampin, phenytoin, carbamazepine, and some antiretrovirals can lower hydrocortisone levels and reduce effectiveness, while CYP3A4 inhibitors like ketoconazole, some HIV protease inhibitors, and certain macrolide antibiotics can increase steroid exposure and side‑effect risk. Concurrent use with NSAIDs, aspirin, or anticoagulants raises the risk of gastrointestinal bleeding; combining with other immunosuppressants (e.g., biologic agents, cytotoxic drugs) further increases infection risk. Live vaccines may be less effective or contraindicated during moderate‑ to high‑dose systemic steroid therapy, and hydrocortisone can alter blood glucose in people taking insulin or oral diabetes medicines. Herbal products such as St. John’s wort (enzyme induction) and high‑dose licorice (additional mineralocorticoid effect) may also interfere.

Food, alcohol, and procedure interactions
Although given parenterally, hydrocortisone’s systemic effects can be worsened by heavy alcohol use, which increases the chance of stomach irritation and bleeding, especially with concurrent NSAIDs. High‑sodium diets may contribute to fluid retention and high blood pressure, while very low‑potassium diets can worsen steroid‑related hypokalemia. Corticosteroids can affect results of certain lab tests (e.g., glucose, cortisol, white blood cell counts) and may need to be considered before allergy skin testing, endocrine testing, or imaging that requires contrast in high‑risk patients.

Precautions and monitoring
Use cautiously in patients with uncontrolled infections, poorly controlled diabetes, hypertension, heart failure, peptic ulcer disease, severe osteoporosis, seizure disorders, psychiatric illness, glaucoma or cataracts, or significant liver or kidney impairment. Long‑term or high‑dose therapy generally requires monitoring of blood pressure, weight and fluid status, blood glucose, electrolytes, complete blood count, bone health (especially in children and postmenopausal women), eye exams, and signs of adrenal suppression or infection. Gradual dose tapering is important after extended courses to allow the adrenal glands to recover.

Q: What is hydrocortisone sodium succinate (Solu‑Cortef) used for?
A: It is an injectable corticosteroid used when oral steroids are not feasible to treat adrenal insufficiency and many severe or emergency corticosteroid‑responsive conditions, such as asthma exacerbations, severe allergic reactions, certain autoimmune and rheumatic diseases, some blood and kidney disorders, and as part of treatment for some cancers.

Q: How fast does IV or IM hydrocortisone start working?
A: After IV injection it reaches high blood levels within minutes, with improvement in blood pressure, breathing, or allergic symptoms often seen within hours; in chronic inflammatory or autoimmune conditions, it may take several days for full benefit.

Q: Is hydrocortisone sodium succinate the same as oral hydrocortisone tablets?
A: They contain the same active hormone (hydrocortisone), but the injectable sodium succinate form is designed to be given IV or IM for rapid effect or when patients cannot take medicine by mouth, whereas tablets are used for ongoing daily treatment once the patient is stable.

Q: What are the biggest risks of short‑term high‑dose hydrocortisone in the hospital?
A: The main concerns are high blood sugar, fluid retention and blood pressure elevation, mood or sleep changes, and increased susceptibility to infection or bleeding in people at risk; these risks rise with dose and duration, so clinicians try to use the lowest effective dose for the shortest time.

Q: Can I receive vaccines while being treated with hydrocortisone sodium succinate?
A: Inactivated (non‑live) vaccines are generally acceptable, but live vaccines may be less effective or not recommended during moderate‑ or high‑dose systemic steroid therapy, so vaccination timing should be planned with your healthcare team.

Storage
Unreconstituted vials should be stored at controlled room temperature (about 68°F to 77°F) and kept in the original packaging until use, away from excess heat, moisture, and light; once mixed with diluent, the solution is normally used promptly in the clinic or hospital and any unused portion is discarded within a short, specified time.

Disposal
Patients typically do not handle disposal, as reconstitution and administration are done by healthcare professionals, but any unused vials at home should not be thrown in household trash or sinks; instead, return them to a clinic, pharmacy take‑back program, or follow local instructions for medication disposal.